share_log

Oppenheimer Reiterates Outperform on Regulus Therapeutics, Maintains $7 Price Target

Benzinga ·  Aug 15 01:36  · Ratings

Oppenheimer analyst Andreas Argyrides reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Outperform and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment